Product Highlight - SYBRAVA

Active ingredient: Inclisiran

Indication: Adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:
• in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or

• alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Dosage & Administration: The recommended dose is 284 mg inclisiran administered as a single subcutaneous injection: Initially, again at 3 months, followed by every 6 months.